Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.

Détails

ID Serval
serval:BIB_F2CED5A51689
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
Périodique
European Journal of Cardio-thoracic Surgery
Auteur(s)
Ampollini L., Soltermann A., Felley-Bosco E., Lardinois D., Arni S., Speck R.F., Weder W., Opitz I.
ISSN
1873-734X (Electronic)
ISSN-L
1010-7940
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
35
Numéro
3
Pages
457-462
Langue
anglais
Notes
Publication types: Journal Article
Résumé
OBJECTIVE: To assess the effect of immuno-chemotherapy on the extent of local tumour recurrence in an established rat model of malignant pleural mesothelioma (MPM).
METHODS: Six days after subpleural inoculation of a syngeneic MPM cell line Interleukin-45 (IL-45), left-sided pneumonectomy and resection of the tumour nodule was performed. Animals were randomised into four treatment groups for intrapleural therapy: control (n=6), 500 microg cytosine phosphate guanosine oligodeoxynucleotide (CpG-ODN) (n=6), cisplatin-fibrin (n=6), cisplatin-fibrin+500 microg CpG (n=6). Six days later the volume of tumour recurrence was assessed, which was the primary endpoint. Secondary endpoints were quantification of the ratio host/tumour cells in the local recurrence and cytokine expression profile in the tumour tissue by real time quantitative PCR (qPCR). T lymphocyte subpopulations in the tumour recurrence tissue were evaluated by immunohistochemistry. Treatment-related toxicity was monitored by measuring blood chemistry and complete blood count.
RESULTS: The volume of tumour recurrence was significantly reduced from 610 mm(3) in the control group to 11.7 mm(3) in the cisplatin-fibrin group (p=0.004) and to 21.8mm(3) in the cisplatin-fibrin+CpG group (p=0.004). Pro-inflammatory cytokines (Interferon-gamma (IFN-gamma), Interleukin-6 (IL-6), Interleukin-12 (IL-12)) were increased after treatment with cisplatin-fibrin+CpG in comparison to cisplatin-fibrin alone but differences were not statistically significant. We found a higher ratio of host/tumour cells in the cisplatin-fibrin+CpG group (45/55%) compared to the cisplatin-fibrin group (27/73%). In comparison to the control group, animals treated with cisplatin-fibrin+CpG showed a higher number of CD8+ T-cells in the tumour tissue. No significant treatment-related toxicity was observed.
CONCLUSIONS: Adjuvant treatment with chemotherapy or immuno-chemotherapy leads to significant reduction of mesothelioma recurrence after surgery in this rat MPM model. Immuno-chemotherapy resulted in an increased recruitment of inflammatory cells to the site of tumourigenesis and elicited higher level of tumour growth inhibiting cytokines.
Mots-clé
Adjuvants, Immunologic/administration & dosage, Animals, Cisplatin/administration & dosage, Combined Modality Therapy/methods, Cytokines/metabolism, Cytosine/metabolism, Immunotherapy/methods, Interferon-gamma/metabolism, Male, Mesothelioma/immunology, Mesothelioma/pathology, Neoplasm Recurrence, Local/pathology, Neoplasm Recurrence, Local/prevention & control, Oligodeoxyribonucleotides/administration & dosage, Pleural Neoplasms/immunology, Pleural Neoplasms/pathology, Random Allocation, Rats, Rats, Inbred F344, Toll-Like Receptors/metabolism, Tumor Burden, Up-Regulation
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/08/2014 14:43
Dernière modification de la notice
20/08/2019 17:20
Données d'usage